Diao et al. found that the average proportion of human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients who initiated medication with the medicines of interest increased from 37.4% before September 2017 to 69.2% afterward. This evidence concerns the gene ERBB2 and breast carcinoma.